Back to Search
Start Over
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.
- Source :
-
Oncoimmunology [Oncoimmunology] 2016 Dec 23; Vol. 6 (3), pp. e1219825. Date of Electronic Publication: 2016 Dec 23 (Print Publication: 2017). - Publication Year :
- 2016
-
Abstract
- Genome sequencing has uncovered an array of recurring somatic mutations in different non-Hodgkin lymphoma (NHL) subtypes. If affecting protein-coding regions, such mutations may yield mutation-derived peptides that may be presented by HLA class I proteins and recognized by cytotoxic T cells. A recurring somatic and oncogenic driver mutation of the Toll-like receptor adaptor protein MYD88 , Leu265Pro (L265P) was identified in up to 90% of different NHL subtype patients. We therefore screened the potential of MYD88 <superscript>L265P</superscript> -derived peptides to elicit cytotoxic T cell responses as tumor-specific neoantigens. Based on in silico predictions, we identified potential MYD88 <superscript>L265P</superscript> -containing HLA ligands for several HLA class I restrictions. A set of HLA class I MYD88 <superscript>L265P</superscript> -derived ligands elicited specific cytotoxic T cell responses for HLA-B*07 and -B*15. These data highlight the potential of MYD88 <superscript>L265P</superscript> mutation-specific peptide-based immunotherapy as a novel personalized treatment approach for patients with MYD88 <superscript>L265P+</superscript> NHLs that may complement pharmacological approaches targeting oncogenic MyD88 L265P signaling.
Details
- Language :
- English
- ISSN :
- 2162-4011
- Volume :
- 6
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Oncoimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 28405493
- Full Text :
- https://doi.org/10.1080/2162402X.2016.1219825